Inhibrx Biosciences (INBX) Change in Accured Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Change in Accured Expenses data on file, last reported at -$1.4 million in Q4 2025.

• On a quarterly basis, Change in Accured Expenses changed N/A year-over-year to -$1.4 million in Q4 2025; TTM through Dec 2025 was -$4.4 million, a 112.15% decrease from a year earlier, with the FY2025 full-year figure at -$4.4 million, down 112.15% from the prior year.
• Change in Accured Expenses for Q4 2025 stood at -$1.4 million, up from -$1.5 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for INBX reached as high as $21.8 million in Q2 2024 and fell as low as -$4.3 million in Q2 2025.
• Historically, Change in Accured Expenses has averaged $6.1 million across 3 years, with a median of $6.0 million in 2024.
• Across the five-year window, Change in Accured Expenses slipped 5.05% in 2024 and tumbled 125.12% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $17.4 million in 2023, then tumbled by 65.33% to $6.0 million in 2024, then plunged by 123.78% to -$1.4 million in 2025.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$1.4 million in Q4 2025, -$1.5 million in Q3 2025, and -$4.3 million in Q2 2025.